User login
Language
Anonymous's groups in this site
User is not a member of any group.
Your groups across all your sites
User is not a member of any group.
Recent Content
Who's online
There are currently 0 users online.
You are here
Regeneron CEO: Trump ‘is a case of one’ and ‘weakest evidence’ for Covid-19 treatment
Primary tabs
Regeneron chief executive Leonard Schleifer on Sunday said President Donald Trump's treatment with the company's experimental antibody cocktail is "a case of one," but stressed ongoing clinical trials still need to show its efficacy.
"The president's case is a case of one, and that's what we call a case report, and it is evidence of what's happening, but it's kind of the weakest evidence that you can get," Schleifer said in an interview on CBS' "Face the Nation."
Schleifer added that there were "some very interesting aspects" in Trump's case, such as his age. He also noted that the president "had some risk factors," and that Trump "did not have his own immune system in gear when he was sick and he got treated" with Regeneron's treatment.
He added that Trump‘s case is "perhaps the most analyzed case report ever" but is "just low down on the evidence scale that we really need."
He noted that clinical trials are the standard for whether it's effective.
"The real evidence has to come about how good a drug is and what it will do on average has to come from these large clinical trials, these randomized clinical trials, which are the gold standard. And those are ongoing," Schleifer said. "We've got some preliminary evidence that we've talked with the FDA, and we're going for an emergency use authorization, because we think it's appropriate at this time."...
Recent Comments